221 CRESCENT ST., WALTHAM, MA
Voting Agreement Among Stockholders
Apogee Therapeutics Enters IL-31R Antibody Discovery Agreement with Paragon
Election Results from Apogee Therapeutics 2026 Annual Meeting
Investor Presentation
Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
Board Resignation - Andrew Gottesdiener and Peter Harwin Step Down
Annual Report to Security Holders
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13D - Ownership Report
PREM14A
S-1MEF